

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
緒方貴次、成田有季哉、 <u>室圭</u>	MSI-high固形癌に対する免疫チェックポイント阻害薬治療と当院におけるMSI検査体制		臨床外科 第75巻第8号	医学書院		2020	958-966
<u>室圭</u>	Lower G. I. /Colon and Rectum Cancer 大腸癌大腸癌における各種希少遺伝子異常の診断と治療		癌と化学療法 Vol.47 第11号	癌と化学療法社		2020	1557-1558
<u>室圭</u>	消化器癌に対する免疫療法の現状と展望		消化器疾患最新の治療2021-2022	南江堂		2021	10-14
<u>川井章</u>	全国骨・軟部腫瘍登録	川井章	肉腫-基礎・臨床の最新知見-	日本臨床社	東京	2020	35-42
<u>川井章</u>	希少がん	川井章	希少がん-がん診療の新たな課題-	日本臨床社	東京	2021	7-16
<u>杉山一彦</u>	悪性脳腫瘍治療に必要な分子標的療法の理解のために	杉山一彦、橋本直哉	悪性脳腫瘍のすべて Neuro-oncologyの教科書	メディカ出版	大阪	2020	10-20
山口隆大、 <u>神波大己</u>	陰茎部分切除術	高橋悟	Urologic Surgery Next 8: 陰茎・陰囊・アンドロロジーの手術	Medical View社	東京都	2021	2-8
<u>西田佳弘</u>	整形外科疾患 骨・軟部腫瘍 (悪性)	福井次矢/高木誠/小室一成	今日の治療指針 2020	医学書院	東京	2020	1179-1180

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Burasakarn P, Higuchi R, <u>Kodera Y</u> (著者19名中19番目)	Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.	Int J Clin Oncol	26(3)	450-460	2021

Yoshino T, Pentheroudakis G, Kodera Y (著者 19名中15番目) et al. JSCO/ESMO/ASCO/JSMO/ TOS	International expert consensus recommendations for tumor-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.	Ann Oncol	31(7)	861-872	2020
Sassa N, Yokoyama Y, Kodera Y (著者9名中8番目) , et al.	Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments.	Int J Clin Oncol	25(5)	929-936	2020
Ishii K, Yokoyama Y, Kodera Y (著者9名中6番目) , et al.	Characteristics of primary and repeated recurrent retroperitoneal liposarcoma: outcomes after aggressive surgeries at a single institution.	Jpn J Clin Oncol	50(12)	1412-1418	2020
Japanese Gastric Cancer Association (corresponding author: Y. Kodera).	Japanese gastric cancer treatment guidelines 2018 (5 th edition).	Gastric Cancer	24(1)	1-21	2021
Mizuno K, Ito T, Kodera Y (著者23名中16番目) , et al.	Real world data of injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.	J Gastroenterol	55(6)	653-661	2020
Nakayama G, Takano N, Kodera Y (著者30名中30番目) , et al.	Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermitted use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (COG-1302 study).	Eur J Cancer	144	61-71	2021
Kobayashi D, Mochizuki Y, Kodera Y (著者9名中9番目) , et al.	Phase II multi- institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).	Int J Clin Oncol	25(10)	1793-1799.	2020
Kanda M, Koike M, Kodera Y (著者11名中11番目) , et al.	An open-label single-arm phase II study of treatment with neoadjuvant S-1 plus cisplatin for clinical stage III squamous cell carcinoma of the esophagus.	Oncologist	25(11)	e1650-e1654	2020
Narita Y, Kadowaki S, Muro K	Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?	Lancet Oncol	21(6)	741-743	2020
Masuishi T, Nakajima TE, Yamazaki K, Hironaka S, Kudo C, Yoshimura K, Muro K	WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.	Future Oncol	16(20)	1417-1424	2020
Murono K, Nozawa H, Nagata H, Ishimaru K, Sonoda H, Emoto S, Kaneko M, Sasaki K, Otani K, Kawai K, Muro K , Ishihara S	Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases.	Int J Colorectal Dis	35(10)	1945-1949	2020

Demetri GD, Antonescu CR, Bjerkehaugen B, <u>Kawai A</u> , et al.	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.	Annals of Oncology: official journal of the European Society for Medical Oncology.	11	1506-1517	2020
Endo M, Takahashi S, Araki N, <u>Kawai A</u> , et al.	Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials.	Cancer Medicine.	11	3656-3667	2020
<u>Kawai A</u> , Higashi T, Shibata T, Yoshida A, et al.	Rare cancers in Japan: definition, clinical features and future perspectives.	Japanese Journal of Clinical Oncology.	50(9)	970-5	2020
Tap WD, Wagner AJ, <u>Kawai A</u> , et al.	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.	JAMA	323 (13)	1266-1276	2020
Yoshida A, Arai Y, <u>Kawai A</u> , et al.	Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.	Histopathology.	76(4)	509-520	2020
Takami H, <u>Sugiyama K</u> , et al.; Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium).	Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.	Neurological Applied Neurobiology.	46	111-124	2020
Takeishi Y, <u>Sugiyama K</u> , et al.	Advantage of high b value diffusion-weighted imaging for differentiation of common pediatric brain tumors in posterior fossa.	Eur J Radiol.		Epub 2020 May 5	2020
Tsuyuguchi S, <u>Sugiyama K</u> , et al.	Primary and Recurrent Growing Teratoma Syndrome in Central Nervous System Nongerminomatous Germ Cell Tumors: Case Series and Review of the Literature.	World Neurosurg.	134	e360-e371	2020
Takayasu T, <u>Sugiyama K</u> , et al.	Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors.	Sci Rep.	10	14326	2020
Nagumo Y, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Kawai K, Okuyama A, Higashi T, <u>Nishiyama H</u> .	Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan.	Int J Urol.	27(2)	157-162	2020

Tanaka K, Kandori S, Nitta S, Chihara I, Kojo K, Nagumo Y, Kimura T, Kojima T, Kawai K, Okuyama A, Higashi T, <u>Nishiyama H.</u>	Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data.	Int J Urol	27(6)	538-542	2020
Nagumo Y, Kawai K, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Okuyama A, Higashi T, <u>Nishiyama H.</u>	Prognostic significance of non-urothelial carcinoma of bladder: analysis of nationwide hospital-based cancer registry data in Japan	Jpn J Clin Oncol.	50(9)	1068-1075	2020
Kimura T, Kawai K, Kandori S, Nitta S, Kojo K, Nagumo Y, Negoro H, Okuyama A, Higashi T, Kojima T, <u>Nishiyama H.</u>	Impact of centralization in primary retroperitoneal sarcoma treatment: analysis using hospital-based cancer registry data in Japan.	Int J Clin Oncol.	25(9)	1687-1694	2020
Nagumo Y, Kawai K, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Okuyama A, Higashi T, <u>Nishiyama H.</u>	Prognostic impact of non-urothelial carcinoma of the upper urinary tract: Analysis of hospital-based cancer registry data in Japan.	Int J Urol.	28(1)	54-60	2021
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, <u>Nishiyama H.</u> Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H.	Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.	Int J Urol.	27(9)	702-709	2020
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, <u>Nishiyama H.</u> Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H.	Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.	Int J Urol.	27(5)	362-368	2020
山口隆大, 杉山豊, <u>神波大己</u>	陰茎癌の診断と治療 特に原発巣について	臨床泌尿器科	73巻11号	832-836	2019
山口隆大, <u>神波大己</u>	泌尿器科診療の最新スタンダード 平成の常識は令和の非常識：陰茎癌	臨床泌尿器科	74巻4号(増刊号)	93-97	2020

松岡歩、 <u>安藤雄一</u>	高齢者のがん薬物療法ガイドラインについて	日本病院薬剤師会雑誌	56巻11号	p1261-1266	2020
<u>Yoshihiro Nishida</u> et al,	Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.	Cancer Science	112	1114-1122	2021
<u>Nishida Y</u> , Urakawa H, Nakayama R, Kobayashi E, Ozaki T, Ae K, Matsumoto Y, Tsuchiya H, Goto T, Hiraga H, Naka N, Takahashi S, Ando Y, Ando M, Kuwatsuka Y, Hamada S, Ueda T, Kawai A.	Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.	Int J Cancer.	148(1)	140-149	2021
石田秀行、近谷賢一、母里淑子、百瀬修二、長田久人、山野智基、富田尚裕、秋山泰樹、平田敬治、六車直樹、高山哲治、 <u>西田佳弘</u> 、石川秀樹	家族性大腸腺腫症に合併するデスマイド腫瘍の診断・治療と重症度分類の提案	遺伝性腫瘍	20巻2号	45-58	2020
<u>西田 佳弘</u>	【泌尿器・生殖器がん、希少がん】希少がん デスマイド腫瘍に対する治療方針 日本と世界の診療ガイドラインにもとづいて	腫瘍内科	26巻4号	407-412	2020
<u>西田 佳弘</u>	【肉腫—基礎・臨床の最新知見—】肉腫の組織型別治療と成績 デスマイド型線維腫症	日本臨床	78巻増刊5 肉腫	682-686	2020
<u>西田 佳弘</u>	骨軟部 良性軟部腫瘍・デスマイド型線維腫症の診断・治療指針	最新主要文献とガイドラインでみる整形外科学レビュー 2021-'22	第1版	239-244	2021
<u>西田 佳弘</u>	Current Organ Topics 骨・軟部腫瘍 骨軟部に対する薬物療法—最近の話題— デスマイドに対するエビデンスに基づいた薬物療法—抗がん剤、分子標的薬	癌と化学療法	48巻3号	342-345	2021
<u>西田 佳弘</u>	希少がん がん診療の新たな課題 II希少がん疾患各論 10.骨軟部腫瘍 (11)悪性末梢神経鞘腫瘍	日本臨床	79巻増刊1	511-515	2021
Arima J, Hiramatsu M, Taniguchi K, Kobayashi T, Tsunematsu I, Kagota S, Sakane J, Suzuki Y, <u>Hirota S</u> .	Multiple gastrointestinal stromal tumors caused by a novel germline <i>KIT</i> gene mutation (Asp820Gly): A case report and literature review.	Gastric Cancer	23	760-764	2020

Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S ; members of the STAR ReGISTry Study Group.	Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.	Gastric Cancer	23	118-125	2020
Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, Serada S, Fujimoto M, Ohkawara T, Nishigaki T, Sugase T, Koh M, Ishida T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Hirota S , Naka T, Mori M, Doki Y.	TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.	Br J Cancer	122	658-667	2020
Yamauchi A, Chinen Y, Chihara T, Ueda M, Ikenaga M, Yamada T, Hirota S .	A case of planar-type gastrointestinal stromal tumor of the transverse colon with perforation.	Clin J Gastroenterol	in press	in press	2021
Yuan J, Kihara T, Kimura N, Hashikura Y, Ohkouchi M, Isozaki K, Takahashi T, Nishida T, Ito A, Hirota S .	Differential expression of CADM1 in gastrointestinal stromal tumors of different sites and with different gene abnormalities.	Pathol Oncol Res	27	602008	2021
飯沼 久恵, 松田 圭二, 橋口 陽二郎	消化器がんにおける血漿エクソソーム内包microRNAのバイオマーカーとしての有用性	分子細胞治療フロンティア		222-230	2020
橋口 陽二郎 , 小澤 毅士, 端山 軍, 野澤 慶次郎, 松田 圭二	【消化器悪性腫瘍診療におけるガイドラインの功罪】大腸癌診療におけるガイドラインの功罪	臨床雑誌外科	82(6)	623-628	2020
松田 圭二, 橋口 陽二郎 , 端山 軍, 土屋 剛史, 野澤 慶次郎	【消化管症候群(第3版) その他の消化管疾患を含めて】空腸、回腸、盲腸、結腸、直腸(下) 腸閉塞 腸重積症	日本臨床	別冊消化管症候群(第3	311-315	2020
Shinto E, Oki E, Shimokawa M, Yamaguchi S, Ishiguro M, Morita M, Kusumoto T, Tomita N, Hashiguchi Y , Tanaka M, Ohnuma S, Tada S, Matsushima T, Hase K.	A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.	Oncology	98(8)	534-541	2020

Kotaro Hama, Yuko Fujiwara, Tamuro Hayama, Tsuyoshi Ozawa, Keijiro Nozawa, Keiji Matsuda, Yojiro Hashiguchi , Kazuaki Yokoyama	Very long-chain fatty acids are accumulated in triacylglycerol and nonesterified forms in colorectal cancer tissues	Scientific reports	11(1)	6163	2020
Hayama T, Ozawa T, Asako K, Kondo R, Ono K, Okada Y, Tsukamoto M, Fukushima Y, Shimada R, Nozawa K, Matsuda K, Fujii S, Fukagawa T, Hashiguchi Y.	Impact of Colon Cancer Location on the Prognostic Significance of Nutritional Indexes and Inflammatory Markers.	In Vivo	35	1261-1269	2021
Yoshida M, Yabuuchi Y, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M ; Japan Duodenal Cancer Guideline Committee.	The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry.	J Gastroenterol Hepatol.	In press	In press	2020
Burasakarn P, Higuchi R, Nunobe S, Kanaji S, Eguchi H, Okada KI, Fujii T, Nagakawa Y, Kanetaka K, Yamashita H, Yamada S, Kuroda S, Aoyama T, Akahori T, Nakagawa K, Yamamoto M, Yamaue H, Sho M , Kodera Y; Japan Duodenal Cancer Guideline Committee.	Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis	J Clin Oncol.	Mar 26(3)	450-460	2021
Tsutsumi K, Kato M, Kakushima N, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M ; Japan Duodenal Cancer Guideline Committee.	Efficacy of endoscopic preventive procedures to reduce delayed adverse events after endoscopic resection of superficial nonampullary duodenal epithelial tumors: a meta-analysis of observational comparative trials.	Gastrointest Endosc	Feb 93(2)	367-374	2021
Shiga K, Nibu KI, Fujimoto Y, Asakage T, Homma A , Mitani H, Ogawa T, Okami K, Muro S, Hirano S, Ueda T, Hanai N, Tsukahara K, Ota I, Yoshimoto S, Shinozaki T, Iwae S, Katagiri K, Saito D, Kiyota N, Tahara M, Takahashi F, Hayashi R.	Multi-institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan.	Laryngoscope.	131	E870-E874	2021

Saito Y, Hayashi R, Iida Y, Mizumachi T, Fujii T, Matsumoto F, Beppu T, Yoshida M, Shinomiya H, Kamiyama R, Kitano M, Yokoshima K, Fujimoto Y, Hama T, Yamashita T, Okami K, Miura K, Fujisawa T, Sano D, Kato H, Minami S, Sugasawa M, Masuda M, Ota I, Iwae S, Kawata R, Monden N, Imai T, Asakage T, Okada M, Yoshikawa T, Tanioka K, Kitayama M, Doi M, Fujii S, Fujii M, Oridate N, Nakamizo M, Yoshimoto S, Homma A , Nibu KI, Yane K.	Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.	Cancer	126	4177-4187	2020
Yoshino T , Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY	JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.	Ann Oncol	Jul;31 (7)	861-872	2020
Jinnouchi F, Yamauchi T, Yurino A, Nunomura T, Nakano M, Iwamoto C, Obara T, Miyawaki K, Kikushige Y, Kato K, Maeda T, Miyamoto T, Baba E , Akashi K, Takenaka K:	Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells.	Blood	135 (19)	1661-1672	2020

Nio K, Tsuchihashi K, Taguchi K, Yoshihiro T, Yamaguchi K, Ito M, Moriyama S, Fukata M, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Wakasaki T, Yasumatsu R, Ariyama H, Kusaba H, Kishimoto J, Akashi K, Baba E	Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib	Int J Surg Oncol	5	e89	2020
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E , Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K:	Randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan, and oxaliplatin (WJOG 6510G)	Eur J Cancer.	135	11-21	2020
Tsuruta N, Tsuchihashi K, Ohmura H, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K, Baba E :	RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.	Biochem Biophys Res Commun.	530(1)	235-239	2020